Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CollaGenex Will Launch Oracea In July With Specialty Sales Force

This article was originally published in The Pink Sheet Daily

Executive Summary

Oracea cleared FDA as the first orally administered, systemically delivered drug to treat rosacea.

You may also be interested in...



Galderma Acquires CollaGenex For $420 Million

Swiss firm fattens dermatological portfolio with acquisition.

Galderma Acquires CollaGenex For $420 Million

Swiss firm fattens dermatological portfolio with acquisition.

CollaGenex, QuatRx Agree To Develop Topical Psoriasis Treatment

CollaGenex tells “The Pink Sheet” DAILY it expects to launch becocalcidiol for treatment of psoriasis between late 2010 and early 2012.

Related Content

Topics

UsernamePublicRestriction

Register

PS064245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel